Statement on CMS Aduhelm decision including a call for Medicare premium refunds.
Alzheimer’s experts call for accelerated withdrawal of Aduhelm; formal petition for removal begins. Approval described as “indefensible in both scientific and clinical terms.”
By: David Zitner Constituencies, individuals, and investing groups have different reasons for investing money money into a profit or a not-for-profit organization and different expectations of what they expect in return. The role of the board of directors of an … Read more
The Right Care Alliance strongly opposes the recent approval by the FDA of aducanumab (Aduhelm), a drug marketed by Biogen for Alzheimer’s disease, and has issued an official statement calling for its withdrawal.
What is your name, class year and major? “My name is Malini Baker. I graduated from Central Washington University and my class year was 2021. My major was business administration, with a specialization in leadership and management.” How did your … Read more
What is your name, university, class year, and major? “My name is Jirehla Dushime, but I go by Jiji. I just graduated from Mt. Hood Community College. It’s in Gresham, Oregon. My major is Psychology. I’m transferring to Fitchburg State … Read more
RCA Intern Kaitlyn Z Varriale shares her experience writing “How Socioeconomic Status Dictates the Health Care Patients with Type One Diabetes Receive in America.” “I took a course through my school where I picked a research topic and spent the … Read more